hollywood actors now in India with bollywood

As of late January 2026, there are several high-profile collaborations between Hollywood and Bollywood, though many remain in the "buzz and negotiation" phase rather than confirmed filming on the ground.

Current Hollywood-Bollywood Collaborations (2026)

Will Smith & Dwayne Johnson (Rumoured): Reports indicate both actors have been in negotiations for major roles (possibly as antagonists) in an upcoming sci-fi epic directed by Atlee, starring alongside Allu Arjun.

Don Lee (Ma Dong-seok): The South Korean-American actor is heavily rumoured to be joining the cast of Spirit, a project directed by Sandeep Reddy Vanga and starring Prabhas.

Sydney Sweeney: Recent reports suggest she has been offered a record-breaking deal (approx. ₹530 crore) for a cross-cultural Bollywood romance project slated for early 2026 production.

Recent/Upcoming International Releases featuring Indian Stars

Deepika Padukone: She has made history by becoming the first Indian actress selected for the Hollywood Walk of Fame Class of 2026.

Hugh Jackman & Kate Hudson: Their biographical musical drama Sleepwalker was released on January 9, 2026, highlighting the continued global presence of Hollywood stars in major theatrical windows shared with Indian cinema.

Adarsh Gourav: The White Tiger actor is set to make a significant "South Indian debut" in 2026 with the film Happy Birthday Uma, further bridging his international acclaim with regional Indian industries.

Historical Crossovers (For Context)

Hollywood actors have a long history of appearing in Bollywood, which often fuels current rumors:

Sylvester Stallone & Denise Richards: Appeared in Kambakkht Ishq.

Ben Kingsley: Starred alongside Amitabh Bachchan in Teen Patti.

Will Smith: Made a cameo in Student of the Year 2.

Would you like more details on a specific actor's project or a list of Bollywood movies shooting abroad in 2026?

US funded vaccine trials

As of late January 2026, there are several U.S.-funded or U.S.-partnered vaccine trials aimed at the Nipah virus, many of which involve collaborations with Indian manufacturing and research institutions.

Key U.S.-Funded Trials & Partnerships

Public Health Vaccines (PHV) - PHV02 Trial:

Funding & Tech: This U.S.-based biotech company, headquartered in Cambridge, MA, is developing PHV02, a single-dose vaccine candidate. It was originally developed by the U.S. National Institutes of Health (NIH) and is funded by CEPI with an award of up to $43.6 million.

Status: After successful Phase I trials in the U.S., it is set to enter Phase II human trials in the region in early 2026, targeting approximately 500 adults and 75 children in Bangladesh to test its efficacy in a real-world hotspot.

Oxford/Serum Institute Collaboration (CEPI-Funded):

The Trial: While developed by the University of Oxford, the ChAdOx1 NipahB vaccine is heavily supported by the Serum Institute of India (SII), the world's largest vaccine manufacturer.

Milestone: In December 2025, it launched the world's first Phase II trial in Bangladesh, involving 306 participants.

Emergency Reserve: The partnership includes creating an "investigational ready reserve" of up to 100,000 doses at the SII facility in Pune, India, for rapid deployment in future outbreaks.

NIH/NIAID mRNA Vaccine (NCT05398796):

The Research: The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. NIH, is conducting a dose-escalation Phase I trial of an experimental mRNA-1215 vaccine.

Goal: This trial evaluates the safety and immune response in healthy adults, serving as a prototype for rapid pandemic response.

Gennova Biopharmaceuticals (CEPI-Funded):

AI Integration: CEPI is providing up to $13.38 million to India-based Gennova to develop a self-amplifying mRNA vaccine.

U.S. Connection: Gennova is collaborating with the Houston Methodist Research Institute in the U.S. to use AI for identifying vaccine targets.

Status Summary (January 2026)

Candidate Developer/Funding Phase Key Partner

PHV02 Public Health Vaccines (U.S.) / CEPI Phase II (Early 2026) U.S. NIH / NIAID

ChAdOx1 NipahB Oxford / CEPI Phase II (Launched Dec 2025) Serum Institute of India

mRNA-1215 NIH / NIAID (U.S.) Phase I U.S. NIH Clinical Center

sa-mRNA Gennova / CEPI Preclinical/Phase I Houston Methodist Research Inst.

Despite these advancements, the WHO confirms that as of January 31, 2026, there are no licensed vaccines yet approved for public use.

>>24201849

Radiation from satellites, iodine and shielding.

>>24201881

Never had much affect on the limited times I have used DMSO for what I was attempting.

>>24201897

Little success with DMSO.

>>24201900

Treat my water with it.